Market Cap | 43.56M | P/E | - | EPS this Y | 57.30% | Ern Qtrly Grth | - |
Income | -111.57M | Forward P/E | -0.63 | EPS next Y | -17.10% | 50D Avg Chg | -4.00% |
Sales | 15.45M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -46.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -87.00% |
Recommedations | 2.00 | Quick Ratio | 3.92 | Shares Outstanding | 187.02M | 52W Low Chg | 36.00% |
Insider Own | 24.77% | ROA | -29.84% | Shares Float | 100.11M | Beta | 0.26 |
Inst Own | 69.82% | ROE | -294.04% | Shares Shorted/Prior | 16.07M/15.81M | Price | 0.68 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 248,227 | Target Price | 6.35 |
Oper. Margin | -438.32% | Earnings Date | May 9 | Volume | 85,872 | Change | 0.19% |
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Cantor Fitzgerald | Overweight | Apr 30, 24 |
Cantor Fitzgerald | Overweight | Apr 19, 24 |
Cantor Fitzgerald | Overweight | Apr 18, 24 |
Needham | Buy | Apr 11, 24 |
Piper Sandler | Overweight | Apr 9, 24 |
Canaccord Genuity | Buy | Mar 21, 24 |
Chardan Capital | Buy | Mar 21, 24 |
JMP Securities | Market Outperform | Mar 20, 24 |
Cantor Fitzgerald | Overweight | Mar 20, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Manning Paul B | 10% Owner 10% Owner | Nov 17 | Buy | 1.63 | 100,000 | 163,000 | 16,566,667 | 11/20/23 |
Alam Kamran | Chief Financial Offi.. Chief Financial Officer | Aug 24 | Sell | 2.33 | 33,000 | 76,890 | 258,042 | 08/25/23 |
Manning Paul B | 10% Owner 10% Owner | Aug 16 | Buy | 0.90 | 16,466,667 | 14,820,000 | 16,466,667 | 08/16/23 |
Stalfort John A III | Director Director | Aug 16 | Buy | 0.9 | 777,778 | 700,000 | 999,381 | 08/16/23 |
Nolan Sean P. | Chief Executive Offi.. Chief Executive Officer | Aug 16 | Buy | 0.90 | 444,444 | 400,000 | 1,535,545 | 08/16/23 |
Donenberg Phillip B. | Director Director | Aug 16 | Buy | 0.90 | 111,111 | 100,000 | 114,111 | 08/16/23 |
Session R.A. II | 10% Owner 10% Owner | Jun 22 | Sell | 0.7 | 28,608 | 20,026 | 8,957,619 | 06/26/23 |
Alam Kamran | Chief Financial Offi.. Chief Financial Officer | Aug 23 | Sell | 3.47 | 3,325 | 11,538 | 266,121 | 08/24/22 |
Alam Kamran | Chief Financial Offi.. Chief Financial Officer | Aug 18 | Sell | 3.71 | 28,675 | 106,384 | 269,446 | 08/22/22 |
PRASAD SUYASH | CMO and Head of R&D CMO and Head of R&D | Jul 05 | Sell | 3.65 | 12,861 | 46,943 | 530,589 | 07/07/22 |
PRASAD SUYASH | CMO and Head of R&D CMO and Head of R&D | Jun 29 | Sell | 3.69 | 50,139 | 185,013 | 543,450 | 07/01/22 |
Manning Paul B | Director Director | Feb 02 | Buy | 7.8 | 201,602 | 1,572,496 | 2,091,704 | 02/04/22 |
Nagendran Sukumar | Director Director | Feb 02 | Buy | 8.01 | 10,000 | 80,100 | 29,226 | 02/03/22 |
Donenberg Phillip B. | Director Director | Feb 02 | Buy | 7.78 | 3,000 | 23,340 | 3,000 | 02/03/22 |